PRLD NASDAQ
Prelude Therapeutics Incorporated
1W: -5.4%
1M: -32.4%
3M: -26.4%
YTD: +34.4%
1Y: +143.1%
3Y: +19.5%
5Y: -89.4%
$3.67
-0.12 (-3.17%)
Weekly Expected Move ±9.4%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-12-03
Earliest Filing
2025-11-04
Latest Filing
acquirer: 1
partner: 1
supplier: 1
Counterparties (Filed by PRLD)
3 relationshipsCompanies named in PRLD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Incyte Corporation | INCY | acquirer | Incyte acquired Prelude's JAK2V617F inhibitor program via an exclusive option agreement and purchased $25M in non-voting | 2025-11-04 | View |
| Jefferies LLC | JEF | partner | Sales agent and/or principal for the Open Market Sale Agreement | 2023-03-15 | View |
| Crisp Partners, LLC | — | supplier | Landlord for the Chestnut Run Lease agreement | 2021-12-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-10 | Regulation FD; Exhibits | View | |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-06-10 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-21 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-04-20 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-15 | Officer/Director Change; Exhibits | View | |
| 2026-03-12 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-04 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2025-10-17 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure | View | |
| 2025-09-19 | Other Events | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-13 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-04-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-28 | Notice of Delisting or Transfer | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR